Literature DB >> 18297516

Therapeutic options in mantle cell lymphoma.

Saar Gill1, David Ritchie.   

Abstract

Mantle cell lymphoma (MCL) is an aggressive lymphoma requiring intensive chemotherapy +/- autologous stem cell transplantation (SCT) to achieve optimal rates of progression-free survival. Here we review the treatment options for patients with newly-diagnosed or relapsed MCL and discuss recent advances in management, including the role of autologous and allogeneic SCT.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18297516     DOI： 10.1080/10428190701851364

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  5 in total

1.  Interleukin 22 signaling promotes cell growth in mantle cell lymphoma.

Authors:  Pascal Gelebart; Zoulika Zak; Jennifer Dien-Bard; Mona Anand; Raymond Lai
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

2.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

Review 3.  Temsirolimus: In relapsed and/or refractory mantle cell lymphoma.

Authors:  Sheridan M Hoy; Kate McKeage
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

4.  Primary mantle-cell non-Hodgkin's lymphoma of the tongue.

Authors:  Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Salvatore Cappabianca; Amerigo Giudice; Giuseppe Colella
Journal:  Int J Hematol       Date:  2008-07-16       Impact factor: 2.490

5.  Mantle cell lymphoma: a rare cause for a swollen palate.

Authors:  Ayah Mohamed; Rachel Cowie; Dáire Shanahan
Journal:  BMJ Case Rep       Date:  2020-10-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.